TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15752879

Group type: EXPERIMENTAL
Intervention: Long-term androgen deprivation
Number of subjects: 1003

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 1003
Study: 11930309

Group type: EXPERIMENTAL
Intervention: RSV immunoglobulin therapy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 9455954

Group type: EXPERIMENTAL
Intervention: SPNT test in WAD group with dizziness
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: SPNT test in WAD group without dizziness
Number of subjects: 75

Group type: COMPARATOR
Intervention: SPNT test in control patients with central and peripheral vertigo and healthy subjects
Number of subjects: 75
Study: 8564323

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) as an adjuvant to treatment as usual
Number of subjects: 31

Group type: COMPARATOR
Intervention: Low-dose lithium therapy
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo maintenance therapy
Number of subjects: 31
Study: 2374273

Group type: EXPERIMENTAL
Intervention: 1200 kcal/d diet for 48 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: 420 kcal/d diet for 16 weeks followed by a conventional reducing diet for the remainder of treatment
Number of subjects: 18
Study: 949108

Group type: EXPERIMENTAL
Intervention: Etomidate infusion (2.55 mg/kg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fentanyl-N2O-O2 anaesthesia with etomidate
Number of subjects: 15

Group type: COMPARATOR
Intervention: High-dose fentanyl anaesthesia
Number of subjects: 15
Study: 31579987

Group type: EXPERIMENTAL
Intervention: Sacha inchi microemulsion (SIME) eye drops
Number of subjects: 64

Group type: COMPARATOR
Intervention: 0.2% hyaluronic acid (HA) control eye drops
Number of subjects: 64
Study: 29314176

Group type: EXPERIMENTAL
Intervention: p53 immunohistochemistry (IHC)
Number of subjects: 60
Study: 26810604

Group type: COMPARATOR
Intervention: Femoral nerve block (FNB)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 157
Study: 24076487

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 110 mg bid
Number of subjects: 9183

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg bid
Number of subjects: 9183

Group type: EXPERIMENTAL
Intervention: Dabigatran plasma concentrations
Number of subjects: 9183

Group type: EXPERIMENTAL
Intervention: Dabigatran exposure
Number of subjects: 9183

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 9183

Group type: EXPERIMENTAL
Intervention: ASA use
Number of subjects: 9183

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 9183
Study: 22713948

Group type: EXPERIMENTAL
Intervention: Morphine (0.1mg/kg I/M)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ketamine (0.5mg/kg I/M)
Number of subjects: 80
Study: 19737527

Group type: EXPERIMENTAL
Intervention: LD LSA-NRC/AS01: 10microg LSA-NRC/0.5ml AS01 (n=5)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: HD LSA-NRC/AS01: 50microg LSA-NRC/0.5ml AS01 (n=13)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LD LSA-NRC/AS02: 10microg LSA-NRC/0.5ml AS02 (n=5)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: HD LSA-NRC/AS02: 50microg LSA-NRC/0.5ml AS02 (n=13)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (non-immunized infectivity controls)
Number of subjects: 36
Study: 17851042

Group type: EXPERIMENTAL
Intervention: 5 to 20 mg/d of oral olanzapine
Number of subjects: 309

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 309
Study: 15983892

Group type: EXPERIMENTAL
Intervention: Multi-drug therapies containing zidovudine, stavudine, or other combinations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 14622636

Group type: EXPERIMENTAL
Intervention: Psychoeducational nursing intervention (detailed information/education session)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 2
Study: 10938759

Group type: EXPERIMENTAL
Intervention: ASHBMP Manual
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (traditional safety fact sheets)
Number of subjects: 150
Study: 8829023

Group type: EXPERIMENTAL
Intervention: 10 mg/d of pravastatin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 500 mg/d of probucol and 600 mg/d of pantethine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Diet plus exercise therapy
Number of subjects: 48
Study: 1349368

Group type: EXPERIMENTAL
Intervention: Atropine plus pralidoxime
Number of subjects: 45

Group type: COMPARATOR
Intervention: Atropine alone
Number of subjects: 45
Study: 3006435

Group type: EXPERIMENTAL
Intervention: Repeated mammographic screening
Number of subjects: 92934

Group type: COMPARATOR
Intervention: Control group (no repeated mammographic screening)
Number of subjects: 92934
Study: 31145006

Group type: EXPERIMENTAL
Intervention: Sexual activity-based HIV pre-exposure prophylaxis (PrEP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-based health workers (CBHW) support
Number of subjects: 0
Study: 29692290

Group type: EXPERIMENTAL
Intervention: Computerized NVS
Number of subjects: 180

Group type: COMPARATOR
Intervention: Interviewer‐administered NVS
Number of subjects: 180
Study: 26732383

Group type: EXPERIMENTAL
Intervention: Thoracoscopic esophagectomy
Number of subjects: 300
Study: 25230684

Group type: EXPERIMENTAL
Intervention: Virtual patient simulation (2-hour fully automated)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Mannequin-based simulation (2-hour facilitator-led)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 57
Study: 22311405

Group type: EXPERIMENTAL
Intervention: Chinese medicine (CM) with Qinggan Lidan Decoction (QLD) during icteric stage and Yigan Jiangmei Decoction (YJD) in non-icteric hyper-aminotransferase stage, alongside Ganciclovir 5 mg/kg every 12 hours for 2 weeks, then 5 mg/kg once a day for 5 days every week for 8 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ganciclovir 5 mg/kg every 12 hours for 2 weeks, then 5 mg/kg once a day for 5 days every week for 8 weeks, with glucurolactone 50 mg three times per day
Number of subjects: 100
Study: 20387548

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Registry studies
Number of subjects: 0
Study: 17618525

Group type: EXPERIMENTAL
Intervention: Ropinirole (0.75 to 15.0 mg/day, mean dose 7.12 mg/day)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 16287635

Group type: EXPERIMENTAL
Intervention: Dance movement therapy (DMT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 12161482

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Raloxifene 180 mg/d
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 10334649

Group type: EXPERIMENTAL
Intervention: 10 mmol/d Mg supplement as Mg(OH)2 (approximately 22 mmol Mg/d) for 28 d
Number of subjects: 26

Group type: COMPARATOR
Intervention: Self-selected diet (approximately 11 mmol Mg/d)
Number of subjects: 26
Study: 8611062

Group type: EXPERIMENTAL
Intervention: Ethanol 0.25 g/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol 0.50 g/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol 0.75 g/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethanol 0 g/kg (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ethanol (all doses)
Number of subjects: 0
Study: 2061363

Group type: EXPERIMENTAL
Intervention: Professional support for high trait anxiety mothers for the first 12 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-professional support for high trait anxiety mothers for the first 12 months
Number of subjects: 100
Study: 6418189

Group type: EXPERIMENTAL
Intervention: alfentanil
Number of subjects: 47

Group type: COMPARATOR
Intervention: fentanyl
Number of subjects: 47
Study: 31425607

Group type: EXPERIMENTAL
Intervention: Singing sessions (8 individual sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (preferred recreational activities such as playing computer games or watching movies)
Number of subjects: 40
Study: 29364063

Group type: EXPERIMENTAL
Intervention: 7.5% sucrose solution (CHO)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Flavour and taste matched placebo solution (PLA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No rinse (CON)
Number of subjects: 18
Study: 27828867

Group type: EXPERIMENTAL
Intervention: Simple maneuver group
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional maneuver group
Number of subjects: 88
Study: 23001190

Group type: EXPERIMENTAL
Intervention: 3 mg of melatonin taken 11 h before baseline sleep midpoint, then 1 h earlier on subsequent days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 21600325

Group type: EXPERIMENTAL
Intervention: PTH (1‐34) treatment
Number of subjects: 39
Study: 19566557

Group type: EXPERIMENTAL
Intervention: Intraoperative cervical dilatation (Group A)
Number of subjects: 400

Group type: COMPARATOR
Intervention: No intraoperative cervical dilatation (Group B)
Number of subjects: 400
Study: 17163236

Group type: EXPERIMENTAL
Intervention: Methotrexate treatment in RA patients
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Methotrexate treatment in PsA patients
Number of subjects: 619

Group type: COMPARATOR
Intervention: Alcohol consumption in RA and PsA patients
Number of subjects: 619
Study: 15520038

Group type: EXPERIMENTAL
Intervention: Health education interventions, particularly interpersonal communication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 11139949

Group type: EXPERIMENTAL
Intervention: Amiodarone (200 mg/day)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Sotalol (320 +/- 20 mg/day)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Propafenone (450 mg/day)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 214

Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Amiodarone vs Propafenone
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Amiodarone and Propafenone
Number of subjects: 214
Study: 9052642

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pilocarpine
Number of subjects: 70
Study: 8364941

Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (I-C)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Ceftazidime plus tobramycin (C&T)
Number of subjects: 106
Study: 3723137

Group type: EXPERIMENTAL
Intervention: 0.5 million units of human lymphoblastoid interferon (Wellferon) three times a week for three months
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 3.0 million units of human lymphoblastoid interferon (Wellferon) three times a week for three months
Number of subjects: 37
Study: 31692188

Group type: EXPERIMENTAL
Intervention: galcanezumab 120 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: galcanezumab 240 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: galcanezumab
Number of subjects: 0
Study: 29911909

Group type: EXPERIMENTAL
Intervention: Bonded spurs
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Chin cup
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Fixed palatal crib
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Removable palatal crib
Number of subjects: 81
Study: 27444494

Group type: EXPERIMENTAL
Intervention: Cyclizine 50 mg (test)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Valoid 50 mg (reference)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 32
Study: 24002927

Group type: EXPERIMENTAL
Intervention: Test formulation of risedronate sodium 35 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference formulation of risedronate sodium 35 mg
Number of subjects: 48
Study: 22918218

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) examination every 2 hr until intracranial brain death flow patterns were found
Number of subjects: 44
Study: 19682803

Group type: EXPERIMENTAL
Intervention: 30 minutes of exercise (70 VO(2max))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Quiet rest
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy control subjects (n=12)
Number of subjects: 12
Study: 18280104

Group type: EXPERIMENTAL
Intervention: Walking exercise program (WEP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard ward care
Number of subjects: 22
Study: 18641105

Group type: EXPERIMENTAL
Intervention: 6.5 mg/kg fospropofol
Number of subjects: 252

Group type: COMPARATOR
Intervention: 2 mg/kg fospropofol
Number of subjects: 252
Study: 14689224

Group type: EXPERIMENTAL
Intervention: Intrarectal instillation of lidocaine-prilocain cream (n=75)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Periprostatic anesthesia with 2% lidocaine (n=80)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group with sonographic gel intrarectally (n=40)
Number of subjects: 198
Study: 11738354

Group type: EXPERIMENTAL
Intervention: Spinal muscular atrophy group (n=96)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Non-affected siblings (n=45)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Healthy controls (n=59)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Older children and adolescents with spinal muscular atrophy (SPM only)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Older children and adolescents with spinal muscular atrophy (Wechsler tests)
Number of subjects: 96
Study: 9376574

Group type: EXPERIMENTAL
Intervention: Combination of 10 microg/kg/d filgrastim and 20 microg/kg/d SCF for 7 days
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Combination of 10 microg/kg/d filgrastim and 25 microg/kg/d SCF for 7 days
Number of subjects: 215

Group type: COMPARATOR
Intervention: Filgrastim alone (10 microg/kg/d for 7 days)
Number of subjects: 215
Study: 8163051

Group type: EXPERIMENTAL
Intervention: Urine glucose self-monitoring (UGSM)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Blood glucose self-monitoring (BGSM)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Standard treatment (Control)
Number of subjects: 181
Study: 3285837

Group type: EXPERIMENTAL
Intervention: 100 mg torasemide
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 200 mg torasemide
Number of subjects: 19

Group type: COMPARATOR
Intervention: 250 mg furosemide
Number of subjects: 19
Study: 11886505

Group type: EXPERIMENTAL
Intervention: Ultraviolet B + Ultraviolet A sunblock (SPF 15)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ultraviolet B sunblock (SPF 15)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-irradiated skin
Number of subjects: 28
Study: 29528807

Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy Skills Training Group (DBTSTG)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Cognitive Therapy Group (CTG)
Number of subjects: 82
Study: 29955803

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment (10 Hz, 120% motor threshold, 4000 pulses/session)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 164
Study: 26956875

Group type: EXPERIMENTAL
Intervention: Compound kushen injection in combination with single-agent chemotherapy
Number of subjects: 370

Group type: COMPARATOR
Intervention: Standard platinum-based doublet chemotherapy
Number of subjects: 370
Study: 24607773

Group type: EXPERIMENTAL
Intervention: Dual ETA/ETB receptor blockade
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Selective ETA blockade
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both selective ETA blockade and dual ETA/ETB blockade
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dual ETA/ETB blockade
Number of subjects: 12
Study: 22490717

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 228

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 228
Study: 20192279

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0
Study: 17299116

Group type: EXPERIMENTAL
Intervention: Higher protein (HP, 30% protein)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal protein (NP, 18% protein)
Number of subjects: 46
Study: 15644655

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg twice daily
Number of subjects: 24
Study: 12117361

Group type: EXPERIMENTAL
Intervention: Donepezil (oral administration for a 5-month period)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (historical control subjects)
Number of subjects: 15
Study: 9933049

Group type: EXPERIMENTAL
Intervention: Doxazosin (titrated to doses of 2, 4, 8, or 12 mg once daily)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study: 8578253

Group type: EXPERIMENTAL
Intervention: Regimen I: follow-up every three months for the first two years and every six months in the third year, thereafter once a year.
Number of subjects: 97

Group type: COMPARATOR
Intervention: Regimen II: follow-up every six months for the first year and once a year thereafter.
Number of subjects: 97

Group type: COMPARATOR
Intervention: Regimen II
Number of subjects: 97
Study: 2104987

Group type: EXPERIMENTAL
Intervention: Ro 15‐3505
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ro 15‐1788
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 836384

Group type: EXPERIMENTAL
Intervention: Resection treatment (partial duodenopancreatectomy, subtotal left pancreatic resection)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Partial duodenopancreatectomy and subtotal left resection
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Preoperative diabetes
Number of subjects: 201
Study: 30869165

Group type: EXPERIMENTAL
Intervention: Perampanel 8 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel 12 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel 4 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel 2, 4, 8, and 12 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28944358

Group type: EXPERIMENTAL
Intervention: Full arch zirconia framework hand-veneered with ceramic
Number of subjects: 24

Group type: COMPARATOR
Intervention: Full arch zirconia framework hand-veneered with composite
Number of subjects: 24
Study: 26662217

Group type: EXPERIMENTAL
Intervention: Selenium and coenzyme Q10
Number of subjects: 437
Study: 24357423

Group type: EXPERIMENTAL
Intervention: Intraperitoneal parastomal mesh placement
Number of subjects: 10
Study: 23151693

Group type: EXPERIMENTAL
Intervention: Triphala
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hi Ora
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Colgate Plax
Number of subjects: 30
Study: 19678778

Group type: EXPERIMENTAL
Intervention: Classical six‐point acupuncture
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Nondefined-point acupuncture
Number of subjects: 68
Study: 17472017

Group type: EXPERIMENTAL
Intervention: Combination therapy (12.5 mg hydrochlorothiazide + 5 mg felodipine)
Number of subjects: 9711

Group type: COMPARATOR
Intervention: Monotherapy (12.5 mg hydrochlorothiazide + placebo)
Number of subjects: 9711
Study: 15703092

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% (10 ml periprostatic)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline solution (10 ml periprostatic)
Number of subjects: 40
Study: 15362028

Group type: EXPERIMENTAL
Intervention: Azathioprine (2 mg/kg/day)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Mesalamine (3 g/day)
Number of subjects: 142
Study: 11878729

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg plus Ondansetron 4 mg
Number of subjects: 177
Study: 9861111

Group type: EXPERIMENTAL
Intervention: 3 s duration of compression of the common carotid artery
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 6 s duration of compression of the common carotid artery
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 10 s duration of compression of the common carotid artery
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 15 s duration of compression of the common carotid artery
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Compression ratio of 40% or more
Number of subjects: 23
Study: 8198930

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg day-1
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg day-1
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 2836565

Group type: EXPERIMENTAL
Intervention: CP at 120 mg/m2 over one hour on day 1, plus fluorouracil (5‐FU) at 1,000 mg/m2 over 24 hours as a continuous infusion on days 1 through 5
Number of subjects: 60

Group type: COMPARATOR
Intervention: CP/5‐FU as in A, plus DDTC at 600 mg/m2 over 30 minutes administered IV exactly 30 minutes after CP infusion, plus DDTC at 200 mg/m2 administered IV over 30 minutes on days 8 and 15
Number of subjects: 60
Study: 29876770

Group type: EXPERIMENTAL
Intervention: Group A (pantoprazole capsules, 40 mg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Group B (pantoprazole tablets, 40 mg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Group C (lansoprazole, 30 mg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Group D (esomeprazole, 20 mg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Group E (rabeprazole, 10 mg)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Total eradication rates
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Gastrointestinal symptoms and stool type
Number of subjects: 175
Study: 28981763

Group type: EXPERIMENTAL
Intervention: Pregnancy and postnatal home visits by Village Health Teams (VHTs)
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: Preventive home visit programme staffed by volunteer VHTs
Number of subjects: 1584

Group type: EXPERIMENTAL
Intervention: VHTs spending an average of 6 hours a week on the programme
Number of subjects: 1584